APT(688617) 证券日报·2025-04-22 23:05Fundraising Overview - The company raised a total of RMB 1,241,248,200.00 through the issuance of 16.67 million shares at a price of RMB 74.46 per share, with a net amount of RMB 1,150,717,825.25 after deducting expenses [2][3] - As of December 31, 2024, the cumulative usage of the raised funds amounted to RMB 1,055,352,821.42, leaving a balance of RMB 153,789,382.03 [3] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure effective use and management of the raised funds [3] - A tripartite supervision agreement has been signed with the underwriter and the bank holding the funds to clarify responsibilities and obligations [3] Fund Usage - The company has not used idle funds for temporary working capital or made any early investments or replacements in fundraising projects during the reporting period [7][10] - The company approved the use of up to RMB 6 billion of temporarily idle funds for cash management, investing in safe and liquid financial products [7] - As of December 31, 2024, the company achieved a net income of RMB 3,149,200 from cash management of idle funds [9] Project Investment - The company plans to invest RMB 827,451,300 in a regional headquarters project, using RMB 337,320,200 from over-raised funds [11][13] - The company has permanently supplemented working capital with surplus funds from the "Vascular Interventional Medical Device Industrial Upgrade Project," amounting to RMB 14,556,000 [14] Fund Changes and Compliance - The company has not experienced any significant changes in project feasibility or failed to meet planned progress during the reporting period [18] - The company has complied with all disclosure obligations regarding the storage and actual use of raised funds, with no violations reported [22] Auditor's Opinion - The accounting firm, Lixin, has issued a report confirming that the company's fundraising storage and usage comply with regulatory requirements [22][23]